MedTrace Logo

Biomarkers for Ventilator-associated Pneumonia

NCT05117125 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-11-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate different peptide biomarkers, variations in the microbiome and patterns in the bacterial transcriptome as prognostic or diagnostic biomarkers of VAP.

Conditions

  • Pneumonia, Ventilator-Associated

Interventions

DIAGNOSTIC_TEST

Heparin-binding protein

Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.

DIAGNOSTIC_TEST

Interleukin-26

Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.

DIAGNOSTIC_TEST

Microbiome

Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.

DIAGNOSTIC_TEST

Bacterial transcriptome

Evaluation of the specificity and sensitivity of the bacterial transcriptome as prognostic biomarker for treatment failure of VAP.

DIAGNOSTIC_TEST

Proteome

Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.

Sponsors & Collaborators

  • Lund University

    collaborator OTHER

  • Region Skane

    lead OTHER

Principal Investigators

  • Magnus Paulsson, PhD MD · Skane University Hospital

  • Fredrik Sjövall, PhD MD · Skane University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-15
Primary Completion
2026-12-31
Completion
2028-12-31

Countries

  • Norway
  • Portugal
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05117125 on ClinicalTrials.gov